Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review Extracorporeal Hemoperfusion Treatment for Covid-19 patients
Archives of Academic Emergency Medicine,
Vol. 8 No. 1 (2020),
7 January 2020
The 2019 novel coronavirus (officially known as severe acute respiratory syndrome coronavirus 2, SARS-CoV2) was first found in Wuhan, China. On February 11, 2020, the World Health Organization (WHO) has declared the outbreak of the disease caused by SARS-CoV2, named coronavirus disease 2019 (COVID-19), as an emergency of international concern. Based on the current epidemiological surveys, some COVID-19 patients with severe infection gradually develop impairment of the respiratory system, acute kidney injury (AKI), multiple organ failure, and ultimately, death. Currently, there is no established pharmacotherapy available for COVID-19. As seen in influenza, immune damage mediated by excessive production of inflammatory mediators contributes to high incidence of complications and poor prognosis. Thus, removal or blocking the overproduction of these mediators potentially aids in reducing the deleterious cytokine storm and improving critically ill patients’ outcomes. Based on previous experience of blood purification to treat cytokine storm syndrome (CSS) in severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), here we aimed to review the current literature on extracorporeal hemoperfusion as a potential therapeutic option for CSS-associated conditions, with a focus on severe COVID-19.
- COVID-19, cytokine storm syndrome, acute respiratory distress syndrome, hemoperfusion
How to Cite
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395(10223):507-13.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine. 2020;8(5):475-81.
Anand D, Ray S, Bhargava S, Das S, Garg A, Taneja S, et al. Proinflammatory versus anti-inflammatory response in sepsis patients: looking at the cytokines. Critical Care. 2014;18(Suppl 2):P13-P.
Barry S, Johnson M, Janossy G. Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone marrow transplantation. 2000;26(6):591-7.
Imashuku S. Clinical features and treatment strategies of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Critical reviews in oncology/hematology. 2002;44(3):259-72.
Bisno A, Brito M, Collins C. Molecular basis of group A streptococcal virulence. The Lancet infectious diseases. 2003;3(4):191-200.
Yokota S. Influenza-associated encephalopathy--pathophysiology and disease mechanisms. Nihon rinsho Japanese journal of clinical medicine. 2003;61(11):1953-8.
Jahrling PB, Hensley LE, Martinez MJ, LeDuc JW, Rubins KH, Relman DA, et al. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proceedings of the National Academy of Sciences. 2004;101(42):15196-200.
Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon‐γ‐related cytokine storm in SARS patients. Journal of medical virology. 2005;75(2):185-94.
Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. The Journal of clinical investigation. 2020;130(5).
Lau SK, Lau CC, Chan K-H, Li CP, Chen H, Jin D-Y, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. Journal of General Virology. 2013;94(12):2679-90.
Yuen K, Wong S. Human infection by avian influenza A H5N1. Hong Kong Medical Journal. 2005.
Österlund P, Pirhonen J, Ikonen N, Rönkkö E, Strengell M, Mäkelä SM, et al. Pandemic H1N1 2009 Influenza A Virus Induces Weak Cytokine Responses in Human Macrophages and Dendritic Cells and Is Highly Sensitive to the Antiviral Actions of Interferons. Journal of Virology. 2010;84(3):1414-22.
Pollard HB, Pollard BS, Pollard JR. Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy. bioRxiv. 2020:2020.04.09.034983.
Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. MedRxiv. 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020;46(5):846-8.
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS medicine. 2006;3(9).
Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nature medicine. 2013;19(10):1313-7.
Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. The Lancet Infectious Diseases. 2014;14(11):1090-5.
Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Critical Care. 2018;22(1):262.
Goldfarb D, Matalon D. Principles and techniques applied to enhance elimination. Goldfrank's toxicologic emergencies: McGraw-Hill, New York; 2006. p. 160-72.
Locket S. Haemodialysis in the treatment of acute poisoning. Proceedings of the Royal Society of Medicine. 1970;63(5):427-30.
Doolan PD, Walsh WP, Wishinsky H. Acetylsalicylic acid intoxication; a proposed method of treatment. Journal of the American Medical Association. 1951;146(2):105-6.
Fiore B, Soncini M, Vesentini S, Penati A, Visconti G, Redaelli A. Multi-scale analysis of the toraymyxin adsorption cartridge. Part II: computational fluid-dynamic study. The International journal of artificial organs. 2006;29(2):251-60.
Vesentini S, Soncini M, Zaupa A, Silvestri V, Fiore GB, Redaelli A. Multi-scale analysis of the toraymyxin adsorption cartridge. Part I: molecular interaction of polymyxin B with endotoxins. The International journal of artificial organs. 2006;29(2):239-50.
Ronco C, Piccinni P, Kellum J. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique. Contributions to nephrology. 2010;167:25-34.
Navas A, Ferrer R, Martinez ML, Goma G, Gili G, Masip J, et al. Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case-control study. Annals of intensive care. 2018;8(1):121.
Muirhead EE, Reid AF. A resin artificial kidney. The Journal of laboratory and clinical medicine. 1948;33(7):841-4.
Pallotta AJ, Koppanyi T. The use of ion exchange resins in the treatment of phenobarbital intoxication in dogs. The Journal of pharmacology and experimental therapeutics. 1960;128:318-27.
SCHREINER GE. The Role of Hemodialysis (Artificial Kidney) in Acute Poisoning. AMA Archives of Internal Medicine. 1958;102(6):896-913.
Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review. Blood purification. 2018;46(4):337-49.
Takeda S, Munakata R, Abe S, Mii S, Suzuki M, Kashiwada T, et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive care medicine. 2010;36(5):906-7.
Binh NG, Manabe T, Co DX, Tuan ND, Thach PT, Kudo K. Polymyxin-B-immobilized-fiber column hemoperfusion with oseltamivir treatment for ARDS due to influenza H1N1/09. Respirology case reports. 2015;3(2):57-60.
Liu Y, Chen X, Wang D, Li H, Huang J, Zhang Z, et al. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy. Journal of immunotherapy (Hagerstown, Md : 1997). 2018;41(9):406-10.
Stahl K, Schmidt BMW, Hoeper MM, Skripuletz T, Möhn N, Beutel G, et al. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. Journal of Critical Care. 2020;57:124-9.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. 2020.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033-4.
Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, et al. Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. Journal of cancer research and clinical oncology. 2020;146(4):1065-77.
Hormati A, Ghadir MR, Zamani F, Khodadadi J, Khodadust F, Afifian M, et al. Are there any association between COVID-19 severity and immunosuppressive therapy? Immunol Lett. 2020;224:12-3.
Ronco C, Navalesi P, Vincent J. Coronavirus epidemic: Preparing for extracorporeal organ support in intensive care. Lancet Respir Med. 2020; piiS2213---2600: 30060---6.
Ankawi G, Fan W, Pomarè Montin D, Lorenzin A, Neri M, Caprara C, et al. A New Series of Sorbent Devices for Multiple Clinical Purposes: Current Evidence and Future Directions. Blood purification. 2019;47(1-3):94-100.
Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2010;14(6):596-602.
Huang Z, Wang SR, Yang ZL, Liu JY. Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2013;17(4):454-61.
Poli EC, Rimmelé T, Schneider AG. Hemoadsorption with CytoSorb(®). Intensive care medicine. 2019;45(2):236-9.
Basu R, Pathak S, Goyal J, Chaudhry R, Goel RB, Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine. 2014;18(12):822-4.
Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Critical Care. 2017;21(1):74.
Hinz B, Jauch O, Noky T, Friesecke S, Abel P, Kaiser R. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. The International journal of artificial organs. 2015;38(8):461-4.
Calabrò MG, Febres D, Recca G, Lembo R, Fominskiy E, Scandroglio AM, et al. Blood Purification With CytoSorb in Critically Ill Patients: Single-Center Preliminary Experience. Artificial organs. 2019;43(2):189-94.
Nephrology ISo. Brescia Renal Covid Task Force : Alberici F et al., GESTIONE DEL PAZIENTE IN DIALISI E CON TRAPIANTO DI RENE IN CORSO DI INFEZIONE DA CORONAVIRUS COVID-19 2020 [Available from: https://www.era-edta.org/en/wp-content/uploads/2020/03/COVID_guidelines_finale_eng-GB.pdf.
FDA has authorized the emergency use of CytoSorb 300 mL device: CytoSorb 300mL device is manufactured under and ISO 13485 and CE Mark approved 2020 [Available from: https://www.fda.gov/media/136866/download.
Friesecke S, Trager K, Schittek GA, Molnar Z, Bach F, Kogelmann K, et al. International registry on the use of the CytoSorb(R) adsorber in ICU patients : Study protocol and preliminary results. Medizinische Klinik, Intensivmedizin und Notfallmedizin. 2019;114(8):699-707.
Intensiva APdMCyT. GUÍAS NACIONALES DE ATENCIÓN DE PACIENTES ADULTOS COVID-19 VERSION 2.0 2019 [Available from: https://medcriticapanama.com/.
Commission CNH. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th Edition) 2020 [Available from: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html.
Canada Go. List of medical devices for expanded use in relation to the COVID-19 pandemic 2020 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/interim-order-importation-sale-medical-devices-covid-19/list-expanded-use.html.
Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. Jama. 2018;320(14):1455-63.
Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive care medicine. 2018;44(12):2205-12.
Nakamura Y, Kitamura T, Kiyomi F, Hayakawa M, Hoshino K, Kawano Y, et al. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study. Critical care (London, England). 2017;21(1):134.
Kodama Y, Takahashi G, Kan S, Masuda T, Ishibe Y, Akimaru R, et al. Use of Direct Hemoperfusion with Polymyxin B-Immobilized Fiber for the Treatment of Septic Shock Complicated with Lemierre Syndrome Caused by Fusobacterium necrophorum. Case reports in critical care. 2019;2019:5740503.
US FDA Approves an Investigational Device Exemption for Spectral Medical PMX to Treat COVID-19 Patients Suffering from Septic Shock 2020 [Available from: https://www.globenewswire.com/news-release/2020/04/14/2015592/0/en/US-FDA-Approves-an-Investigational-Device-Exemption-for-Spectral-Medical-PMX-to-Treat-COVID-19-Patients-Suffering-from-Septic-Shock.html.
- Abstract Viewed: 220 times
- pdf Downloaded: 94 times